Kymera Investor Presentation Deck

● ● ● ● KT-253: Emerging Clinical Data Support Therapeutic Hypothesis for MDM2 Degrader KT-253, unlike SMIs, overcomes the feedback loop which up-regulates MDM2 production and in doing so more effectively stabilizes the tumor suppressor p53 KT-253 inhibits tumor cell growth with picomolar activity and is more than 200-fold more potent than clinically active MDM2 SMIs, enabling intermittent dosing to improve therapeutic index Interim Phase 1a data from Arm A show evidence of target engagement and p53 pathway activation and initial signs of antitumor activity without DLTS including typical hematological toxicity Arm B (high grade myeloid malignancies including AML) enrollment initiated Additional clinical and preclinical data supporting biomarker-based patient selection strategy to be disclosed in 2024 KYMERA ©2023 KYMERA THERAPEUTICS, INC. First-in-class Opportunity to Address p53 WT Tumors Across a Variety of Tumor Types First degrader against a clinically proven but inadequately drugged target, MDM2 Profound single agent activity in preclinical liquid and solid tumor models and initial evidence of antitumor activity in patients in Phase 1a Clinical development strategy includes accelerated registration path in p53 WT tumors with high sensitivity to degrader mechanism such as AML, lymphomas and solid tumors PAGE 41

View entire presentation